Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosbretabulin + Chemo in Anaplastic Thyroid Cancer (FACT2)
NCT01701349Phase 3Withdrawn
- Sponsor
- Oncotelic Therapeutics, Inc.
- Start
- Mar 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fosbretabulin in anaplastic thyroid carcinoma (ATC), sponsored by Oncotelic Therapeutics, Inc.. Planned start Mar 2015; status: withdrawn.
02
Drugs
fosbretabulin
03
Conditions
anaplastic thyroid carcinoma (ATC)
Beyond the preview
Go deeper on NCT01701349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01701349.